Clinical and Experimental Pediatrics

The Korean Pediatric Society (대한소아청소년과학회)
권호 표지
DOI QR코드

DOI QR Code

Influence of vascular endothelial growth factor (VEGF) and endostatin on coronary artery lesions in Kawasaki disease

가와사끼병에서 혈청 VEGF 및 endostatin의 변화가 관상동맥병변의 발생에 미치는 영향

  • Kim, Seon A (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Jung, Bum Suk (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Yoon, Jong Seo (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Han, Ji Whan (Department of Pediatrics, College of Medicine, The Catholic University of Korea) ;
  • Lee, Joon Sung (Department of Pediatrics, College of Medicine, The Catholic University of Korea)
  • 김선아 (가톨릭대학교 의과대학 소아과학교실) ;
  • 정범석 (가톨릭대학교 의과대학 소아과학교실) ;
  • 윤종서 (가톨릭대학교 의과대학 소아과학교실) ;
  • 한지환 (가톨릭대학교 의과대학 소아과학교실) ;
  • 이준성 (가톨릭대학교 의과대학 소아과학교실)
  • Received : 2007.10.30
  • Accepted : 2007.11.29
  • Published : 2007.12.15
Download PDF
⟨ Previous Next ⟩

Abstract

Purpose : Recently, there has been several studies to clarify the pathogenesis of Kawasaki disease (KD) and the relations of VEGF and endostatin that act on vascular endothelial cells to the coronary artery complications. In this report, we measured serum levels of VEGF and endostatin in acute and subacute phases of KD to assess the change of these levels and the relations to the development of coronary artery lesions (CAL). Methods : Twenty six patients were diagnosed and treated for KD between January, 2001 and July, 2005 at Kangnam St. Mary's Hospital, the Catholic University of Korea. They were divided into those with and without CAL. Serum levels of VEGF and endostatin were measured during acute and subacute phases and compared to those measured in healthy and disease control groups. Results : Serum levels of VEGF were increased in KD but no differences were noted in KD with and without CAL. Serum levels of endostatin were decreased in the acute phase of KD, however they were recovered in the subacute phase of KD, regardless of CAL. The VEGF/endostatin ratio was increased in KD. KD without CAL showed a relative decrease in this ratio during the subacute phase. Significant positive correlations were found between serum VEGF and WBC count, VEGF and ESR, VEGF/endostatin ratio and ESR in the acute phase of KD. Conclusion : Analysis of factors influencing the vascular endothelium such as VEGF and endostatin will help to clarify the etiology of KD and the pathogenesis of CAL.

목 적 : 최근 가와사끼병에서 혈관내피세포에 작용하는 VEGF와 endostatin의 혈청 농도를 측정하여 가와사끼병의 병인을 밝히고 관상동맥합병증과의 연관성을 찾으려는 여러 연구가 있다. 이 연구에 따르면 두 인자가 모두 가와사끼병에서 관상동맥합병증과 연관이 있다고 하였다. 따라서, 저자들은 가와사끼병의 급성기와 아급성기에 혈청 VEGF와 혈청 endostatin의 농도를 측정하여 어떤 변화가 있는지, 관상동맥병변의 발생과 어떤 연관성이 있는지 알아보고자 하였다. 방 법 : 2004년 1월부터 2005년 7월까지 가톨릭대학교 강남성모병원에서 가와사끼병으로 진단받고 입원 치료를 받은 환아 26명을 대상으로 하였다. 관상동맥병변의 발생 유무에 따라 두 군으로 나누었고 각각 급성기와 아급성기에 혈청 VEGF와 혈청 endostatin의 농도를 측정하였으며 건강 대조군 및 질병 대조군과 비교 분석하였다. 결 과 : 가와사끼병 환아군에서 혈청 VEGF 농도는 증가되었으나 급성기와 아급성기의 비교에서 유의한 차이는 없었고, 관상동맥병변의 유무에 따라 나눈 두 군 간에도 유의한 차이는 없었다. 혈청 endostatin 농도는 가와사끼병 환아의 급성기에서 감소되었고, 관상동맥병변의 유무와 관계없이 급성기에 감소하였다가 아급성기에 회복되었다. 가와사끼병 환아군에서 VEGF/endostatin 비는 증가되었고, 관상동맥병변이 없었던 군에서는 급성기에 비하여 아급성기에 VEGF/endostatin 비가 감소하였으나, 관상동맥병변이 있었던 군에서는 아급성기에 VEGF/endostatin 비가 감소하지 않았다. 가와사끼병 환아군에서 급성기의 혈청 VEGF와 백혈구 수 간, 혈청 VEGF와 ESR 치 간, 그리고 VEGF/endostatin 비와 ESR 치 간에는 양의 상관관계가 있었다. 결 론 : VEGF와 endostatin 같은 혈관내피세포에 작용하는 인자를 측정, 비교하는 것은 가와사끼병의 병인과 관상동맥병변 발생의 병태생리를 밝히는데 도움이 될 것이라고 생각된다.

Keywords

Acknowledgement

Supported by : 가톨릭대학교

References

  1. Newburger JW, Fulton DR. Kawasaki disease. Curr Opin Pediatr 2004;16:508-14 https://doi.org/10.1097/01.mop.0000137796.23813.64
  2. Kim DS. Kawasaki disease. Yonsei Med J 2006;47:759-72 https://doi.org/10.3349/ymj.2006.47.6.759
  3. Royle J, Burgner D, Curtis N. The diagnosis and management of Kawasaki disease. J Paediatr Child Health 2005;41: 87-93 https://doi.org/10.1111/j.1440-1754.2005.00555.x
  4. Freeman AF, Shulman ST. Kawasaki disease: summary of the American Heart Association guidelines. Am Fam Physician 2006;74:1141-8
  5. Schroh AM, Dominguez P, Laghezza LB, Melonari PA, Olguin M, Miatello R. Kawasaki disease: heart disease during childhood. Rev Esp Cardiol 2006;59:387-90 https://doi.org/10.1016/S1885-5857(06)60777-9
  6. Leung DY, Schlievert PM, Meissner HC. The immunopathogenesis and management of Kawasaki syndrome. Arthritis Rheum 1998;41:1538-47 https://doi.org/10.1002/1529-0131(199809)41:9<1538::AID-ART3>3.0.CO;2-M
  7. Suzuki A, Miyagawa-Tomita S, Komatsu K, Nishikawa T, Sakomura Y, Horie T, et al. Active remodeling of the coronary arterial lesions in the late phase of Kawasaki disease: immunohistochemical study. Circulation 2000;101:2935-41 https://doi.org/10.1161/01.CIR.101.25.2935
  8. Terai M, Yasukawa K, Narumoto S, Tateno S, Oana S, Kohno Y. Vascular endothelial growth factor in acute Kawasaki disease. Am J Cardiol 1999;83:337-9 https://doi.org/10.1016/S0002-9149(98)00864-9
  9. Maeno N, Takei S, Masuda K, Akaike H, Matsuo K, Kitajima I, et al. Increased serum levels of vascular endothelial grow th factor in Kawasaki disease. Pediatr Res 1998;44: 596-9 https://doi.org/10.1203/00006450-199810000-00021
  10. Kim MS, Kim KS. The study of serum vascular endothelial growth factor in the acute febrile phase of Kawasaki disease. J Korean Pediatr Soc 2002;45:114-9
  11. Park MH, Jung HL, Yang JH, Shim JY, Kim DS, Shim JW, et al. Serum vascular endothelial growth factor as a predictive risk factor for the occurrence of coronary artery lesions in Kawasaki disease. J Korean Pediatr Soc 2003;46: 811-6
  12. asukawa K, Terai M, Shulman ST, Toyozaki T, Yajima S, Kohno Y, et al. Systemic production of vascular endothelial growth factor and fms-like tyrosine kinase-1 receptor in acute Kawasaki disease. Circulation 2002;105:766-9 https://doi.org/10.1161/hc0602.103396
  13. Kariyazono H, Ohno T, Khajoee V, Ihara K, Kusuhara K, Kinukawa N, et al. Association of vascular endothelial growth factor (VEGF) and VEGF receptor gene polymorphisms with coronary artery lesions of Kawasaki disease. Pediatr Res 2004;56:953-9 https://doi.org/10.1203/01.PDR.0000145280.26284.B9
  14. Hamamichi Y, Ichida F, Yu X, Hirono KI, Uese KI, Ha moto I, et al. Neutrophils and mononuclear cells express vascular endothelial growth factor in acute Kawasaki disease: its possible role in progression of coronary artery lesions. Pediatr Res 2001;49:74-80 https://doi.org/10.1203/00006450-200101000-00017
  15. Takeshita S, Kawamura Y, Takabayashi H, Yoshida N, Nonoyama S. Imbalance in the production between vascular endothelial growth factor and endostatin in Kawasaki disease. Clin Exp Immunol 2005;139:575-9 https://doi.org/10.1111/j.1365-2249.2005.02714.x
  16. Berse B, Brown LF, Van de Water L, Dvorak HF, Senger DR. Vascular permeability factor (vascular endothelial growth factor) gene is expressed differentially in normal tissues, macrophages, and tumors. Mol Biol Cell 1992;3:211-20 https://doi.org/10.1091/mbc.3.2.211
  17. Schuch G, Heymach JV, Nomi M, Machluf M, Force J, Atala A, et al. Endostatin inhibits the vascular endothelial growth factor-induced mobilization of endothelial progenitor cells. Cancer Res 2003;63:8345-50
  18. Yamaguchi N, Anand-Apte B, Lee M, Sasaki T, Fukai N, Shapiro R, et al. Endostatin inhibits VEGF-induced endothelial cell migration and tumor growth independentl zinc binding. EMBO J 1999;18:4414-23 https://doi.org/10.1093/emboj/18.16.4414
  19. Research Committee on Kawasaki Disease. Report of subcommittee on standardization of diagnostic criteria and reporting of coronary artery lesions in Kawasaki disease. Tokyo, Japan : Ministry of Health and Welfare, 1984
  20. Ayusawa M, Sonobe T, Uemura S, Ogawa S, Nakamura Y, Kiyosawa N, et al. Revision of diagnostic guidelines for Kawasaki disease (the 5th revised edition). Pediatr Int 2005; 47:232-4 https://doi.org/10.1111/j.1442-200x.2005.02033.x
  21. Ohno T, Yuge T, Kariyazono H, Igarashi H, Joh-o K, Kinugawa N, et al. Serum hepatocyte growth factor combined with vascular endothelial growth factor as a predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2002;161:105-11 https://doi.org/10.1007/s00431-001-0860-1
  22. Ohno T, Igarashi H, Inoue K, Akazawa K, Joho K, Hara T. Serum vascular endothelial growth factor: a new predictive indicator for the occurrence of coronary artery lesions in Kawasaki disease. Eur J Pediatr 2000;159:424-9 https://doi.org/10.1007/s004310051300